At least seven fires and one injury that were related to some FreeStyle Libre glucose monitor products have led the US Food and Drug Administration to issue a Class I recall, which suggests that use of a device could cause “serious injuries or death.”
At least seven fires and one injury that were related to some FreeStyle Libre glucose monitor products have led the US Food and Drug Administration to issue a Class I recall, the agency’s strongest, which suggests that use of a device could cause “serious injuries or death.” The FDA says there have been 206 incidents related to these monitors, which became available in 2017.
Without insulin, sugar can build up in the bloodstream and break down the body’s own fat and muscle. A continuous glucose monitor uses a handheld device that reads a sensor placed on the back of the person’s upper arm to capture real-time glucose levels. The monitor used with the FreeStyle Libre line uses lithium-ion batteries similar to those in a mobile phone.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Sinaloa drug cartel member extradited to US on international drug trafficking, firearms chargesA high-ranking member of the Sinaloa Cartel who worked closely with El Chapo was extradited to the U.S. Saturday to face international drug trafficking charges.
Consulte Mais informação »
FDA to require prescriptions for livestock antibioticsRight now, farmers in Alabama can purchase antibiotics like penicillin over the counter. Once the new FDA requirement is put in place, a prescription will be required for those purchases.
Consulte Mais informação »
The evolution of antibiotic resistance is associated with collateral drug phenotypes in Mycobacterium tuberculosis - Nature CommunicationsHere using drug susceptibility profiling, genomics and evolutionary studies the authors provide strategies to exploit collateral drug responses in Mycobacterium tuberculosis to prevent the emergence of drug resistance.
Consulte Mais informação »
FDA forces unproven premature birth drug Makena off marketThe Food and Drug Administration is ordering an unproven drug intended to prevent premature births off the market. The decision announced Thursday follows years of delays by drugmaker Covis Pharma, which repeatedly asked the FDA for more time to study the drug. Makena is the only medication to receive FDA approval to help reduce the risk of early births. The drug was approved in 2011 based on early research suggesting it helped women with a history of miscarriages and premature deliveries. But follow-up studies failed to show the drug resulted in better results for women or their babies.
Consulte Mais informação »
FDA forces unproven premature birth drug Makena off marketThe Food and Drug Administration is ordering an unproven drug intended to prevent premature births off the market
Consulte Mais informação »
FDA forces unproven premature birth drug Makena off marketThe Food and Drug Administration is ordering an unproven drug intended to prevent premature births off the market.
Consulte Mais informação »